Bacil Pharma Ltd — Important, 09-07-2026: Company Update

Bacil Pharma's board has approved a Rights Issue to raise up to ₹50 Cr, aiming to strengthen its financial position. To support this and future capital needs, the board also approved increasing the authorized share capital by ₹45 Cr, bringing the total to ₹65 Cr, pending shareholder approval. The company has appointed key intermediaries for the Rights Issue process. Additionally, two independent directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, have resigned from the board.